Other3

Aspen Neuroscience, Inc.

Total Value

$NaN

Filing Date

Oct 29, 2026

1 transactions

Trade Summary

On Oct 29, 2026, McDevitt Damien, Insider, reported $NaN of Aspen Neuroscience, Inc. (ASPE) across 1 transactions. The filing covers company securities and reflects balanced net activity of $NaN. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: McDevitt Damien
Role: Insider
Location: SAN DIEGO, CA

Filing Details

Filing Date: Oct 29, 2026
Transaction Date: Oct 29, 2026
Accession Number: 0001193125-26-439047
Form Type: 3

Want live alerts when McDevitt Damien trades again?

Download Insider Trades to track ASPE, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)Shares of Common Stock held by Damien McDevitt and Pamela Marnell-McDevitt, Co-trustees of the Marnell-McDevitt Family Trust dated May 2, 2019, of which 93,607 shares remain subject to performance-based vesting conditions and to repurchase by the Issuer if such conditions are not met or upon termination of the Reporting Person's service.
(F2)Shares of Common Stock held by Finn McDevitt, Trustee of the Finn McDevitt 2025 Irrevocable Trust.
(F3)Shares of Common Stock held by Aran McDevitt, Trustee of the Aran McDevitt 2025 Irrevocable Trust.
(F4)Shares of Common Stock held by Conor McDevitt, Trustee of the Conor McDevitt 2025 Irrevocable Trust.
(F5)The option was granted on December 16, 2024. The option is fully vested and exercisable.
(F6)The option was granted on November 26, 2025. The shares subject to the option were previously eligible to vest in 48 equal monthly installments beginning on December 20, 2025. In August 2026, the vesting schedule was amended such that the unvested shares subject to the option as of July 20, 2026, shall vest in equal monthly installments through November 20, 2031, subject to the Reporting Person's continuous service through each vesting date.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

McDevitt Damien

(Last)

(First)

(Middle)

10835 ROAD TO THE CURE, SUITE 100

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/29/2026

3. Issuer Name and Ticker or Trading Symbol
Aspen Neuroscience, Inc. [ ASPE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	485,751	I	See Footnote 1.⁽¹⁾
Common Stock	25,299	I	See Footnote 2.⁽²⁾
Common Stock	25,299	I	See Footnote 3.⁽³⁾
Common Stock	25,299	I	See Footnote 4.⁽⁴⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽⁵⁾	12/15/2034	Common Stock	196,820	$8.7	D
Stock Option (Right to Buy)	⁽⁶⁾	11/25/2035	Common Stock	387,063	$5.74	D

Explanation of Responses:

1. Shares of Common Stock held by Damien McDevitt and Pamela Marnell-McDevitt, Co-trustees of the Marnell-McDevitt Family Trust dated May 2, 2019, of which 93,607 shares remain subject to performance-based vesting conditions and to repurchase by the Issuer if such conditions are not met or upon termination of the Reporting Person's service.

2. Shares of Common Stock held by Finn McDevitt, Trustee of the Finn McDevitt 2025 Irrevocable Trust.

3. Shares of Common Stock held by Aran McDevitt, Trustee of the Aran McDevitt 2025 Irrevocable Trust.

4. Shares of Common Stock held by Conor McDevitt, Trustee of the Conor McDevitt 2025 Irrevocable Trust.

5. The option was granted on December 16, 2024. The option is fully vested and exercisable.

6. The option was granted on November 26, 2025. The shares subject to the option were previously eligible to vest in 48 equal monthly installments beginning on December 20, 2025. In August 2026, the vesting schedule was amended such that the unvested shares subject to the option as of July 20, 2026, shall vest in equal monthly installments through November 20, 2031, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

Exhibit 24 - Power of Attorney President and Chief Executive Officer

	By: /s/ Jeffrey L. Boerneke, as Attorney-in-Fact	10/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 3 as rendered by the SEC from accession 0001193125-26-439047.

Aspen Neuroscience, Inc.

Trade Summary

Company Information

Insider Information

Filing Details

Want live alerts when McDevitt Damien trades again?

Footnotes

SEC Form 3

SEC Filing

SEC Form 3